Text Size

Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2009 by Royal Marsden NHS Foundation Trust.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01034696
First received: December 16, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted

December 16, 2009
December 16, 2009
May 2009
January 2010   (final data collection date for primary outcome measure)
The proportion of patients with significant pain and the proportion of patients with a negative score on the pain management index (PMI) [ Designated as safety issue: No ]
Same as current
No Changes Posted
  • Proportion of patients with neuropathic pain. [ Designated as safety issue: No ]
  • Potential predictors of pain. The variables tested as potential risk factors will be age, tumour type, gender and treatment type. [ Designated as safety issue: No ]
  • We will also seek to identify potential predictors of pain intensity in patients that do have pain. In addition to the risk factors already mentioned above, duration and cause of pain will also be tested in this case as potential pain predictors. [ Designated as safety issue: No ]
Same as current
 
 
 
Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting
Pain Prevalence and Risk Factors Amongst Sarcoma/Melanoma Oncology Outpatients. A Baseline, Cross Sectional Study Towards a Pain Free Hospital

The primary objective of this research project is to estimate the number of patients with sarcoma or melanoma attending an outpatients clinic that are in pain or have unmet pain needs.
 
Observational
Observational Model: Cohort
Time Perspective: Prospective
 
Non-Probability Sample

Participants attending sarcoma and melanoma out patients clinics at the Royal Marsden Hospital.
  • Sarcoma
  • Melanoma
 
 
 

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
250
January 2010
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of sarcoma or melanoma cancer
  • Able to respond to an assessment in written English.
  • Able to provide informed consent to participate in the study.

Exclusion Criteria:

  • Patients whose health would be compromised by participation in the study
Both
18 Years and older
No
Contact: Dr John Williams 02078082954 john.williams@rmh.nhs.uk
United Kingdom
 
NCT01034696
CCR3224
No
Dr John Williams, Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
 
Principal Investigator: Dr John Williams Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP